Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-chain fatty acids induce tissue plasminogen activator in airway epithelial cells via GPR41&43.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2018
Same author

Chronic airway inflammation provides a unique environment for B cell activation and antibody production.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016
Same author

Elevated presence of myeloid dendritic cells in nasal polyps of patients with chronic rhinosinusitis.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2014
Same author

Reduced expression of antimicrobial PLUNC proteins in nasal polyp tissues of patients with chronic rhinosinusitis.

Allergy·2012
Same author

Acute hepatitis and rash to fluconazole.

Allergy·2003
Same author

Hypersensitivity to IFN-alpha.

Allergy·2001

Related Experiment Video

Updated: Jul 12, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Immunotherapy: parameters of assessment.

R Patterson, L C Grammer, M A Shaughnessy

    The Journal of Allergy and Clinical Immunology
    |August 1, 1985
    PubMed
    Summary

    Allergen immunotherapy is safe and effective, with rising IgG antibody levels providing the key immunologic explanation for its clinical benefits in patients. This immune response is crucial for assessing treatment efficacy, especially for hard-to-avoid allergens.

    Area of Science:

    • Immunology
    • Allergy Research
    • Clinical Trials

    Background:

    • Allergen immunotherapy (AIT) is established as safe and effective for specific aeroallergens.
    • Mechanisms of AIT's protective effects are not fully understood, with limited evidence for proposed actions.
    • Blocking antibodies, identified 50 years ago, represent a potential key mechanism.

    Purpose of the Study:

    • To investigate the immunologic mechanisms underlying the clinical efficacy of allergen immunotherapy.
    • To determine the role of specific antibody responses, particularly IgG, in AIT's effectiveness.
    • To establish appropriate assessment methods for AIT, especially for challenging aeroallergens.

    Main Methods:

    • Analysis of eight successive clinical studies demonstrating AIT efficacy.

    More Related Videos

    Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
    08:32

    Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

    Published on: June 7, 2018

    Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
    12:42

    Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

    Published on: January 7, 2019

    Related Experiment Videos

    Last Updated: Jul 12, 2026

    Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
    09:31

    Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

    Published on: October 2, 2015

    Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
    08:32

    Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

    Published on: June 7, 2018

    Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
    12:42

    Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

    Published on: January 7, 2019

  • Monitoring of serum levels of IgE and IgG antibodies before and after immunotherapy.
  • Assessment of safety and immunologic responses in controlled study conditions.

    • Main Results:

    • Clinical efficacy of AIT was consistently demonstrated across eight studies.
    • Serum IgE antibody levels remained unchanged or slightly increased post-immunotherapy.
    • A significant rise in serum IgG antibody levels was observed in all eight studies.

    Conclusions:

    • The significant increase in IgG antibody levels provides a logical immunologic explanation for AIT's clinical efficacy.
    • Demonstrating safety and a robust IgG antibody response is an appropriate assessment method for AIT, particularly for aeroallergens that cannot be avoided or easily studied.
    • Further research into blocking antibodies and IgG's role can refine AIT protocols and patient selection.